117 related articles for article (PubMed ID: 3358891)
1. Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics and first dose effect of prazosin.
Lennard MS; McGourty JC; Silas JH
Br J Clin Pharmacol; 1988 Feb; 25(2):276-8. PubMed ID: 3358891
[TBL] [Abstract][Full Text] [Related]
2. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.
Lennard MS; Jackson PR; Freestone S; Tucker GT; Ramsay LE; Woods HF
Br J Clin Pharmacol; 1984 Jun; 17(6):679-85. PubMed ID: 6743465
[TBL] [Abstract][Full Text] [Related]
3. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.
Lennard MS; Tucker GT; Woods HF
Clin Pharmacokinet; 1986; 11(1):1-17. PubMed ID: 2868819
[TBL] [Abstract][Full Text] [Related]
4. Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.
Peart GF; Boutagy J; Shenfield GM
Eur J Clin Pharmacol; 1987; 33(4):397-402. PubMed ID: 3443146
[TBL] [Abstract][Full Text] [Related]
5. Metabolic oxidation of methaqualone in extensive and poor metabolisers of debrisoquine.
Oram M; Wilson K; Burnett D; Al-Dabbagh SG; Idle JR; Smith RL
Eur J Clin Pharmacol; 1982; 23(2):147-50. PubMed ID: 7140803
[TBL] [Abstract][Full Text] [Related]
6. Genetically determined oxidation capacity and the disposition of debrisoquine.
Sloan TP; Lancaster R; Shah RR; Idle JR; Smith RL
Br J Clin Pharmacol; 1983 Apr; 15(4):443-50. PubMed ID: 6849780
[TBL] [Abstract][Full Text] [Related]
7. Timolol metabolism and debrisoquine oxidation polymorphism: a population study.
Lennard MS; Lewis RV; Brawn LA; Tucker GT; Ramsay LE; Jackson PR; Woods HF
Br J Clin Pharmacol; 1989 Apr; 27(4):429-34. PubMed ID: 2719899
[TBL] [Abstract][Full Text] [Related]
8. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.
Lennard MS; Silas JH; Freestone S; Trevethick J
Br J Clin Pharmacol; 1982 Aug; 14(2):301-3. PubMed ID: 6125207
[TBL] [Abstract][Full Text] [Related]
9. Evidence for the polymorphic oxidation of debrisoquine in the Thai population.
Wanwimolruk S; Patamasucon P; Lee EJ
Br J Clin Pharmacol; 1990 Feb; 29(2):244-7. PubMed ID: 2306417
[TBL] [Abstract][Full Text] [Related]
10. Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.
McGourty JC; Silas JH; Lennard MS; Tucker GT; Woods HF
Br J Clin Pharmacol; 1985 Dec; 20(6):555-66. PubMed ID: 2868742
[TBL] [Abstract][Full Text] [Related]
11. Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics.
Lewis RV; Lennard MS; Jackson PR; Tucker GT; Ramsay LE; Woods HF
Br J Clin Pharmacol; 1985 Mar; 19(3):329-33. PubMed ID: 2859048
[TBL] [Abstract][Full Text] [Related]
12. Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation.
Danhof M; Idle JR; Teunissen MW; Sloan TP; Breimer DD; Smith RL
Pharmacology; 1981; 22(6):349-58. PubMed ID: 7267701
[TBL] [Abstract][Full Text] [Related]
13. Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol.
Lennard MS; Tucker GT; Silas JH; Woods HF
Xenobiotica; 1986 May; 16(5):435-47. PubMed ID: 2874665
[TBL] [Abstract][Full Text] [Related]
14. Debrisoquine oxidation phenotype and susceptibility to lung cancer.
Speirs CJ; Murray S; Davies DS; Biola Mabadeje AF; Boobis AR
Br J Clin Pharmacol; 1990 Jan; 29(1):101-9. PubMed ID: 2153391
[TBL] [Abstract][Full Text] [Related]
15. Stereoselective metabolism of metoprolol in Caucasians and Nigerians--relationship to debrisoquine oxidation phenotype.
Lennard MS; Tucker GT; Woods HF; Silas JH; Iyun AO
Br J Clin Pharmacol; 1989 May; 27(5):613-6. PubMed ID: 2757883
[TBL] [Abstract][Full Text] [Related]
16. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics of chlorpropamide.
Kallio J; Huupponen R; Pyykkö K
Eur J Clin Pharmacol; 1990; 39(1):93-5. PubMed ID: 2276394
[TBL] [Abstract][Full Text] [Related]
17. Debrisoquine oxidation in an Australian population.
Peart GF; Boutagy J; Shenfield GM
Br J Clin Pharmacol; 1986 May; 21(5):465-71. PubMed ID: 3718805
[TBL] [Abstract][Full Text] [Related]
18. Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation.
Philip PA; Lewis LD; James CA; Rogers HJ
Cancer Chemother Pharmacol; 1988; 22(4):321-4. PubMed ID: 3168145
[TBL] [Abstract][Full Text] [Related]
19. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.
Evans DA; Mahgoub A; Sloan TP; Idle JR; Smith RL
J Med Genet; 1980 Apr; 17(2):102-5. PubMed ID: 7381862
[TBL] [Abstract][Full Text] [Related]
20. Discovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development.
Gleiter CH; Aichele G; Nilsson E; Hengen N; Antonin KH; Bieck PR
Br J Clin Pharmacol; 1985 Jul; 20(1):81-4. PubMed ID: 4027140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
